Goldman Sachs remains Neutral on ARIAD Pharmaceuticals (Nasdaq: ARIA) with a price target of $7 following recent Q4 results from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE